Clinical trial
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced…
NCT00075686 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00075686 |
|---|---|
| Title | S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer |
| Official title | A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH Cancer and Leukemia Group B NCIC Clinical Trials Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, gemcitabine hydrochloride |
| Enrollment | 766 |
| Start date | Jan 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | Apr 1, 2009 |
| First posted | Jan 13, 2004 |
| Last update posted | Nov 17, 2015 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: